SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Testing blood and CSF in people with epilepsy: a practical guide.

Sutton, F; Barca, D; Komoltsev, I; Craiu, D; Guekht, A; von Oertzen, T; Cock, HR (2020) Testing blood and CSF in people with epilepsy: a practical guide. Epileptic Disord, 22 (4). pp. 381-398. ISSN 1950-6945 https://doi.org/10.1684/epd.2020.1191
SGUL Authors: Cock, Hannah Rutherford

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (427kB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (981kB) | Preview

Abstract

Laboratory investigations, whilst not essential to the diagnosis of seizures or of epilepsy, can be fundamental to determining the cause and guiding management. Over 50% of first seizures have an acute symptomatic cause, including a range of metabolic, toxic or infectious cause. The same triggers can precipitate status epilepticus, either de novo or as part of a deterioration in control in individuals with established epilepsy. Some, such as hypoglycaemia or severe hyponatraemia, can be fatal without prompt identification and treatment. Failure to identify seizures associated with recreational drug or alcohol misuse can lead to inappropriate AED treatment, as well as a missed opportunity for more appropriate intervention. In individuals with established epilepsy on treatment, some laboratory monitoring is desirable at least occasionally, in particular, in relation to bone health, as well as in situations where changes in AED clearance or metabolism are likely (extremes of age, pregnancy, comorbid disorders of renal or hepatic function). For any clinician managing people with epilepsy, awareness of the commoner derangements associated with individual AEDs is essential to guide practice. In this article, we review indications for tests on blood, urine and/or cerebrospinal fluid in patients presenting with new-onset seizures and status epilepticus and in people with established epilepsy presenting acutely or as part of planned monitoring. Important, but rare, neurometabolic and genetic disorders associated with epilepsy are also mentioned.

Item Type: Article
Additional Information: Cette œuvre est mise à disposition selon les termes de la Licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Keywords: CSF, blood, epilepsy, investigations, seizure, therapeutic drug monitoring, CSF, blood, epilepsy, investigations, seizure, therapeutic drug monitoring, 1103 Clinical Sciences, Neurology & Neurosurgery
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: Epileptic Disord
ISSN: 1950-6945
Language: eng
Dates:
DateEvent
1 August 2020Published
13 August 2020Published Online
2 June 2020Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 32782232
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112270
Publisher's version: https://doi.org/10.1684/epd.2020.1191

Actions (login required)

Edit Item Edit Item